文献速递脊柱关节炎其他结缔组织病

FIB-4可作为银屑病关节炎肝病高风险患者的有效筛查工具:基于FibroScan的横断面研究

FIB-4 as an effective screening tool in psoriatic arthritis patients at high-risk for liver disease: a cross-sectional study using FibroScan.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

本研究为单中心横断面研究,纳入89例因疑似MASLD相关CSLD而转诊评估的PsA患者,评估FIB-4、ELF和BARD评分对CSLD的筛查性能。CSLD患病率为61.8%,多变量分析显示高血压、BMI>30 kg/m2和FIB-4≥1.3与CSLD独立相关;FIB-4≥1.3的阴性预测值达98.0%,支持其作为一线筛查工具。

要点

  • 高风险PsA患者中CSLD常见,患病率61.8%。
  • FIB-4≥1.3与CSLD独立相关,阴性预测值98.0%。
  • 高血压和BMI>30 kg/m2亦为CSLD独立相关因素。

核心结论

  • CSLD在高风险PsA患者中常见,且与代谢危险因素强相关。
  • FIB-4≥1.3具有高阴性预测值,支持其作为一线筛查工具。

研究设计与样本

  • 单中心横断面研究,纳入89例因疑似MASLD继发CSLD而转诊进行肝脏评估的PsA患者。

主要发现

  • CSLD在55/89例患者(61.8%)中被识别。
  • 单变量分析中,高甘油三酯血症、高血压、他汀使用、BMI>30 kg/m2、较高ELF和FIB-4评分及LSM升高与CSLD显著相关。
  • 多变量回归中,高血压、BMI>30 kg/m2和FIB-4≥1.3保持独立相关。
  • FIB-4≥1.3的敏感性47.8%、特异性77.2%、阳性预测值6.1%、阴性预测值98.0%。
  • MTX暴露与CSLD无关。

关键数值与推荐

  • CSLD定义为FibroScan肝硬度测量(LSM)>10 kPa和/或超声和/或活检显示MASLD继发的脂肪变性/纤维化/肝硬化。
  • FIB-4≥1.3的敏感性47.8%、特异性77.2%、阳性预测值6.1%、阴性预测值98.0%。

临床怎么用

  • 对高风险PsA患者可采用包含FIB-4的筛查路径,FIB-4≥1.3者进一步行FibroScan。
  • 该路径可能有助于指导更安全的处方并改善结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the performance of non-invasive screening tools in identifying metabolic dysfunction-associated steatotic liver disease (MASLD) causing clinically significant liver disease (CSLD) in PsA patients at high risk for liver disease, and to identify factors associated with CSLD. METHODS: A single-centre, cross-sectional study of PsA patients referred for liver assessment due to suspected CSLD secondary to MASLD was conducted. Fibrosis-4 (FIB-4), Enhanced Liver Fibrosis (ELF) and BARD (BMI, aspartate aminotransferase/alanine transaminase ratio and Diabetes) scores were calculated using routine laboratory and clinical data. Liver imaging was performed as clinically indicated, including FibroScan in most patients. CSLD was defined as liver stiffness measurement (LSM) >10 kPa on FibroScan and/or US and/or biopsy showing steatosis/fibrosis/cirrhosis secondary to MASLD. Univariable and multivariable analyses identified variables independently associated with CSLD. RESULTS: Eighty-nine PsA patients were included (median age 51.0 years; 57.3% male). Cardiometabolic comorbidities were common: 96.6% had one or more metabolic risk factor and 69.7% were obese. CSLD was identified in 55/89 patients (61.8%). In univariable analyses, hypertriglyceridaemia, hypertension, statin use, BMI >30 kg/m2, higher ELF and FIB-4 scores, and elevated LSM were significantly associated with CSLD. In multivariable regression, hypertension, BMI >30 kg/m2 and FIB-4 ≥1.3 remained independently associated. FIB-4 ≥1.3 demonstrated sensitivity of 47.8%, specificity of 77.2%, positive predictive value of 6.1% and negative predictive value of 98.0%. MTX exposure was not associated with CSLD. CONCLUSIONS: CSLD is common in high-risk PsA patients and strongly associated with metabolic risk factors. FIB-4 ≥1.3 had high negative predictive value, supporting its use as a first-line screening tool. Routine MASLD screening using a pathway incorporating FIB-4 followed by FibroScan may inform safer prescribing and improve outcomes.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Meridor K, Harrison SR, Parker R, et al. FIB-4 as an effective screening tool in psoriatic arthritis patients at high-risk for liver disease: a cross-sectional study using FibroScan. Rheumatology (Oxford). 2026. PMID: 41330696. doi:10.1093/rheumatology/keaf640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。